Bicycle Therapeutics PLC Sponsored ADR

BCYC Healthcare Biotechnology

Bicycle Therapeutics PLC Sponsored ADR’s revenue for fiscal 2025 (year ended December 2025) was $72.6 million, up 105.8% from fiscal 2024. In the quarter to June 2026, revenue fell 78.5%, EPS grew 36.8% and free cash flow grew 32.0%, each against the same quarter a year earlier. Revenue growth for five consecutive years.

3.46 0.14 −3.89%
Market cap
$181.4M
P/E
0.0×
Fwd P/E
−1.8×
Dividend yield
—
F-score
2/9
Altman Z
0.99
Beneish M
−1.37
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(34.59%) (31.21%) (33.84%) (32.30%)
Piotroski F-Score
2 2 2 3
ROA
(28.47%) (26.15%) (28.51%) (26.47%)
ROIC
0.00% 0.00% 0.00% (64,747.54%)
Return on Tangible Assets
(37.06%) (34.65%) (38.03%) (35.77%)
Average Days of Receivables
866.33 178.99 235.21 282.79
Free Cash Flow per Share
(3.49) (3.64) (3.32) (2.98)
Free Cash Flow
(241.87) (252.02) (231.69) (208.28)
Other line items

Show all line items

Columns are period end dates